科微学术

微生物学通报

2025年6月1日 周日
首页 > 过刊浏览>2022年第49卷第3期 >1167-1176. DOI:10.13344/j.microbiol.china.210772
PDF HTML阅读 XML下载 导出引用 引用提醒
铜绿假单胞菌异质性耐药的研究进展
作者:
基金项目:

广东省基础与应用基础研究基金(2021A1515011080，2020A1515010850)


Research progress on heteroresistance of Pseudomonas aeruginosa
Author:
  • ZHANG Yahui

    ZHANG Yahui

    Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, Guangdong, China;Zhejiang Ocean University, Zhoushan 316022, Zhejiang, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • LI Wenru

    LI Wenru

    Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, Guangdong, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • XIE Xiaobao

    XIE Xiaobao

    Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Guangzhou 510070, Guangdong, China
    在期刊界中查找
    在百度中查找
    在本站中查找
  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [63]
    • |
  • 相似文献 [20]
    • | | |
  • 文章评论
    摘要:

    异质性耐药是指细菌中的同源亚群对某种抗生素表现出不同的敏感性，被认为是细菌由敏感进化成完全耐药的中间阶段。常规的临床检验无法有效检测出异质性耐药，这对临床治疗用药造成了巨大的威胁，引起患者的反复感染和用药失败。铜绿假单胞菌作为医院内感染的主要条件致病菌之一，其耐药机制已被广泛研究，而异质性耐药研究则相对较少。本文主要就铜绿假单胞菌的异质性耐药研究进行了梳理，并对异质性耐药从表型特征、机制和检测方法等方面进行了简要阐明。

    Abstract:

    Heteroresistance refers to the different susceptibilities of homologous bacterial subgroups to an antibiotic,which is considered as the intermediate stage of bacterial evolution from susceptibility to resistance.Conventional clinical tests cannot effectively detect heteroresistance,which poses a serious threat to clinical treatment and medication,resulting in repeated infection and medication failure of patients.Pseudomonas aeruginosa is one of the main opportunistic pathogens causing nosocomial infection.Despite the extensive research on the drug resistance mechanism of P. aeruginosa,the studies about the heteroresistance of this bacterium are rare.In this review,we summarized the related studies about the heteroresistance of P. aeruginosa and expounded the phenotypic characteristics,mechanism,and detection methods of heteroresistance.

    参考文献
    [1] 胡付品,郭燕,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,等. 2019年CHINET三级医院细菌耐药监测[J].中国感染与化疗杂志, 2020, 20(3):233-243 Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Zhang ZX, Ji P, Xie Y, et al. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019[J]. Chinese Journal of Infection and Chemotherapy, 2020, 20(3):233-243(in Chinese)
    [2] 胡付品,郭燕,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,等. 2018年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志, 2020, 20(1):1-10 Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Zhang ZX, Ji P, Xie Y, et al. CHINET surveillance of bacterial resistance in China:2018 report[J]. Chinese Journal of Infection and Chemotherapy, 2020, 20(1):1-10(in Chinese)
    [3] 胡付品,郭燕,朱德妹,汪复,蒋晓飞,徐英春,张小江,张朝霞,季萍,谢轶,等. 2017年CHINET中国细菌耐药性监测[J].中国感染与化疗杂志, 2018, 18(3):241-251 Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Zhang ZX, Ji P, Xie Y, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China:report from the CHINET Surveillance Program, 2017[J]. Chinese Journal of Infection and Chemotherapy, 2018, 18(3):241-251(in Chinese)
    [4] Yin SP, Chen P, You B, Zhang YL, Jiang B, Huang GT, Yang ZC, Chen Y, Chen J, Yuan ZQ, et al. Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a Chinese burn center from 2011 to 2016[J]. Frontiers in Microbiology, 2018, 9:1135
    [5] Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, et al. Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain[J]. Antimicrobial Agents and Chemotherapy, 2017, 61(11):e01589-17
    [6] Oliver A, Mulet X, López-Causapé C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones[J]. Drug Resistance Updates, 2015, 21/22:41-59
    [7] 侯琦.细菌的异质性耐药[J].临床输血与检验, 2003(3):238-240 Hou Q. Heteroresistance of bacteria[J]. Journal of Clinical Transfusion and Laboratory Medicine, 2003(3):238-240(in Chinese)
    [8] Kayser FH, Benner EJ, Hoeprich PD. Acquired and native resistance of Staphylococcus aureus to cephalexin and other β-lactam antibiotics[J]. Applied Microbiology, 1970, 20(1):1-5
    [9] Alexander HE, Leidy G. Influence of streptomycin on type b Haemophilus influenzae[J]. Science, 1946, 104(2692):101-102
    [10] El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance:an emerging field in need of clarity[J]. Clinical Microbiology Reviews, 2015, 28(1):191-207
    [11] Pournaras S, Ikonomidis A, Markogiannakis A, Spanakis N, Maniatis AN, Tsakris A. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems[J]. Journal of Medical Microbiology, 2007, 56(Pt 1):66-70
    [12] Machado D, Antunes J, Simões A, Perdigão J, Couto I, McCusker M, Martins M, Portugal I, Pacheco T, Batista J, et al. Contribution of efflux to colistin heteroresistance in a multidrug resistant Acinetobacter baumannii clinical isolate[J]. Journal of Medical Microbiology, 2018, 67(6):740-749
    [13] Charretier Y, Diene SM, Baud D, Chatellier S, Santiago-Allexant E, Van Belkum A, Guigon G, Schrenzel J. Colistin heteroresistance and the involvement of the PmrAB regulatory system in Acinetobacter baumannii[J]. Antimicrob Agents Chemother, 2018, 62(9):e00788-18
    [14] SØGaard P, Gahrn-Hansen B. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae[J]. Acta Pathologica Microbiologica Scandinavica Series B:Microbiology, 1986, 94B (1/6):351-356
    [15] 吴婷婷,芮志莲,徐敏,邵启祥.铜绿假单胞菌亚胺培南异质性耐药的机制[J].江苏大学学报(医学版), 2018, 28(4):297-301 Wu TT, Rui ZL, Xu M, Shao QX. Mechanisms of heterogeneous drug resistance against imipenem in Pseudomonas aeruginosa[J]. Journal of Jiangsu University:Medicine Edition, 2018, 28(4):297-301(in Chinese)
    [16] 马幸延,李虹霖,鲁洋,蔡依玫,张伟铮,曾建明,陈茶,黄彬.铜绿假单胞菌对碳青霉烯类抗生素异质性耐药的临床特征与危险因素分析[J].热带医学杂志, 2019, 19(4):398-403 Ma XY, Li HL, Lu Y, Cai YM, Zhang WZ, Zeng JM, Chen C, Huang B. Clinical features and risk factors analysis of carbapenems heteroresistance in Pseudomonas aeruginosa[J]. Journal of Tropical Medicine, 2019, 19(4):398-403(in Chinese)
    [17] 何建春.铜绿假单胞菌和大肠埃希菌碳青霉烯异质性耐药及机制研究[D].重庆:重庆医科大学硕士学位论文, 2018 He JC. Study on the molecular mechanism of carbapenem heteroresistance in Pseudomonas aeruginosa and Escherichia coli[D]. Chongqing:Master's Thesis of Chongqing Medical University, 2018(in Chinese)
    [18] Xu Y, Zheng XK, Zeng WL, Chen T, Liao WL, Qian J, Lin J, Zhou C, Tian XB, Cao JM, et al. Mechanisms of heteroresistance and resistance to imipenem in Pseudomonas aeruginosa[J]. Infection and Drug Resistance, 2020, 13:1419-1428
    [19] 许磊.铜绿假单胞菌多粘菌素异质性耐药及联合药敏研究[D].杭州:浙江大学硕士学位论文, 2016 Xu L. Colistin heteroresistance and drug combination study of Psoudomonas aeruglnosa[D]. Hangzhou:Master's Thesis of Zhejiang University, 2016(in Chinese)
    [20] Hermes DM, Pormann Pitt C, Lutz L, Teixeira AB, Ribeiro VB, Netto B, Martins AF, Zavascki AP, Barth AL. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and-resistant Pseudomonas aeruginosa[J]. Journal of Medical Microbiology, 2013, 62(8):1184-1189
    [21] Lin J, Xu CQ, Fang RC, Cao JM, Zhang XC, Zhao YJ, Dong GF, Sun Y, Zhou TL. Resistance and heteroresistance to colistin in Pseudomonas aeruginosa isolates from Wenzhou, China[J]. Antimicrobial Agents and Chemotherapy, 2019, 63(10):e00556-19
    [22] Jia XJ, Ma WJ, He JC, Tian XL, Liu H, Zou H, Cheng S. Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia[J]. International Journal of Antimicrobial Agents, 2020, 55(3):105832
    [23] Pournaras S, Ikonomidis A, Neou E, Kantzanou M, Maniatis AN, Tsakris A. Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam[J]. Journal of Antimicrobial Chemotherapy, 2008, 61(3):757-758
    [24] He JC, Jia XJ, Yang SS, Xu XY, Sun KL, Li CY, Yang TX, Zhang LP. Heteroresistance to carbapenems in invasive Pseudomonas aeruginosa infections[J]. International Journal of Antimicrobial Agents, 2018, 51(3):413-421
    [25] Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance[J]. Nature Reviews Microbiology, 2019, 17(8):479-496
    [26] 傅豪,罗琦霞,肖永红.多黏菌素异质性耐药的研究进展及临床意义[J].中国抗生素杂志, 2020, 45(11):1103-1108 Fu H, Luo QX, Xiao YH. Research progress and clinical significance of polymyxin heteroresistance[J]. Chinese Journal of Antibiotics, 2020, 45(11):1103-1108(in Chinese)
    [27] Nicoloff H, Hjort K, Levin BR, Andersson DI. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification[J]. Nature Microbiology, 2019, 4(3):504-514
    [28] Anderson SE, Sherman EX, Weiss DS, Rather PN. Aminoglycoside heteroresistance in Acinetobacter baumannii AB5075[J]. mSphere, 2018, 3(4):e00271-18
    [29] 刘宇阳,蓝锴,熊蕊,鲁洋,蔡依玫,向国秀,陈茶,黄彬.耐碳青霉烯类大肠埃希菌对替加环素异质性耐药的机制[J].分子诊断与治疗杂志, 2021, 13(2):178-182 Liu YY, Lan K, Xiong R, Lu Y, Cai YM, Xiang GX, Chen C, Huang B. Mechanisms of tigecycline heteroresistance in carbapenem-resistant Escherichia coli[J]. Journal of Molecular Diagnostics and Therapy, 2021, 13(2):178-182(in Chinese)
    [30] Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital[J]. Journal of Antimicrobial Chemotherapy, 2001, 47(4):399-403
    [31] Operario DJ, Koeppel AF, Turner SD, Bao YD, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, et al. Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis[J]. PLoS One, 2017, 12(5):e0176522
    [32] Sun L, Talarico S, Yao LN, He LH, Self S, You YH, Zhang HF, Zhang YY, Guo YJ, Liu GD, et al. Droplet digital PCR-based detection of clarithromycin resistance in Helicobacter pylori isolates reveals frequent heteroresistance[J]. Journal of Clinical Microbiology, 2018, 5吶???场慥渰朰‰?吹??倸爼敢癲愾汛攳渳捝攠?潩晫?癮慯湭捯潵洠祏挬椠湐?楮湯瑰敯牵浬敯摵椠慍琬攠??楯?卯瑭慩灤桩祳氠潁挮漠捉据當獥?慴畩牧敡畴獩??椠??嘠?卡???慰湥摮?桭攠瑨敥牴潥杲敯湲敥潳畩獳?噡?卣??慡浭潯湮杧?浤敩瑦桦楥捲楥汮汴椠湳?牱敵獥楮獣瑥愠湴瑹??楳?卯??椼????楥?慤畯牭敯畮獡??楡??睵楧瑩桮?桳楡朼栯?瘾愠湣捬潩浮祩捣楡湬?浩楳湯楬浡慴汥?椠湲桥楶扥楡瑬潳爠祦?捲潴湨捥敲渠瑤物慶瑥楲潳湩獴?楛湊?吮愠楊睯慵湲?慡?洠畯汦琠楍捥敤湩瑣敡牬?獍畩牣癲敯楢汩汯慬湯捧敹?猠琲田搱礱??财?ㄨ??㈠???嬺?崵???漱电爵游愼汢?漾晛″?楝挠牐潯扵楲潮污潲条祳???洠浉畫湯潮汯潭杩祤?慳渠摁??湍晡敲捫瑯楧潩湡???に???????????ぴ???ぁ??戠牔?孡??嵩??慁渮搠?噥????牲楥獳灩敳汴污?????乯愠灣楡敲牢??????敳爠物敮爠愼?????呮桥慴牯灢?????嘠慢癡極歭潡汮慮湩畩???￣偛潊桝氮????割敮慡摬?呯????潴獩業湩杣敲牯?卩???呃牨敥湭瑯??卥??数瑹?愠氲?‰?測琠椵戵椨漶琩椺挱‰昵愵椭氱田爵收?浢敲搾楛愳琵敝搠?扯祵?慮?牲敡獳椠獓琬愠湋瑲?獳畴扯瀠潉瀬甠汖慲瑩楯潮湩?楇測??楫??湯瑭敩牤潩扳愠捁琬攠牐?捵汬潯慵挠慁攬??楥?孲?嵰??乬慯瑵甠牄攬??楳捡牫潲扩楳漠汁漮朠祃???ち????????っ???扦爠?孥??嵰??略晭漠畨牥?乥??割慥潳?剳側??卣敥挠潩湮搠愼物社?浬敥瑢慳扩潥汬楬瑡攠獰?慥湵摭?潮瑩桡敥爠?猯浩愾汣污?浢潡汰敥据略汭敡獳?愠猨?楐湃琩攭牰捲敯汤汵畣汩慮牧?灣慬瑩桮潩杣敡湬椠捩?獯楬条湴慥汳猠孯?崠?????匯??椮挠爼潩戾楰潮汥潵杭祯??敡瑥琼支物猾????ㄠ???????ㄠ??ㄠぃ???ical Microbiology, 2010, 48(7):2601-2604
    [36] Mei SC, Gao YL, Zhu CT, Dong CL, Chen YW. Research of the heteroresistance of Pseudomonas aeruginosa to imipenem[J]. International Journal of Clinical and Experimental Medicine, 2015, 8(4):6129-6132
    [37] Qin X, Zhou C, Zerr DM, Adler A, Addetia A, Yuan SH, Greninger AL. Heterogeneous antimicrobial susceptibility characteristics in Pseudomonas aeruginosa isolates from cystic fibrosis patients[J]. mSphere, 2018, 3(2):e00615-17
    [38] Ikonomidis A, Tsakris A, Kantzanou M, Spanakis N, Maniatis AN, Pournaras S. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa[J]. FEMS Microbiology Letters, 2008, 279(1):36-39
    [39] Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS. Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection[J]. mBio, 2018, 9(2):e02448-17
    [40] Hong YK, Ko KS. PmrAB and PhoPQ variants in colistin-resistant Enterobacter spp. isolates in Korea[J]. Current Microbiology, 2019, 76(5):644-649
    [41] Telke AA, Olaitan AO, Morand S, Rolain JM. soxRS induces colistin hetero-resistance in Enterobacter asburiae and Enterobacter cloacae by regulating the acrAB-tolC efflux pump[J]. Journal of Antimicrobial Chemotherapy, 2017, 72(10):2715-2721
    [42] Silva A, Sousa AM, Alves D, Lourenco A, Pereira MO. Heteroresistance to colistin in Klebsiella pneumoniae is triggered by small colony variants sub-populations within biofilms[J]. Pathogens and Disease, 2016, 74(5):ftw036
    [43] Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes[J]. Molecular Microbiology, 2008, 68(1):223-240
    [44] Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Høiby N. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms[J]. Antimicrobial Agents and Chemotherapy, 2004, 48(4):1168-1174
    [45] Balasubramanian D, Schneper L, Merighi M, Smith R, Narasimhan G, Lory S, Mathee K. The regulatory repertoire of Pseudomonas aeruginosa AmpCß-lactamase regulator AmpR includes virulence genes[J]. PLoS One, 2012, 7(3):e34067
    [46] Xu KD, Stewart PS, Xia F, Huang CT, McFeters GA. Spatial physiological heterogeneity in Pseudomonas aeruginosa biofilm is determined by oxygen availability[J]. Applied and Environmental Microbiology, 1998, 64(10):4035-4039
    [47] Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(1):317-323
    [48] Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms[J]. Antimicrobial Agents and Chemotherapy, 2004, 48(7):2659-2664
    [49] Williamson KS, Richards LA, Perez-Osorio AC, Pitts B, McInnerney K, Stewart PS, Franklin MJ. Heterogeneity in Pseudomonas aeruginosa biofilms includes expression of ribosome hibernation factors in the antibiotic-tolerant subpopulation and hypoxia-induced stress response in the metabolically active population[J]. Journal of Bacteriology, 2012, 194(8):2062-2073
    [50] Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms[J]. Antimicrobial Agents and Chemotherapy, 2000, 44(3):640-646
    [51] Soares A, Roussel V, Pestel-Caron M, Barreau M, Caron F, Bouffartigues E, Chevalier S, Etienne M. Understanding ciprofloxacin failure in Pseudomonas aeruginosa biofilm:persister cells survive matrix disruption[J]. Frontiers in Microbiology, 2019, 10:2603
    [52] Allison KR, Brynildsen MP, Collins JJ. Heterogeneous bacterial persisters and engineering approaches to eliminate them[J]. Current Opinion in Microbiology, 2011, 14(5):593-598
    [53] Conlon BP, Rowe SE, Lewis K. Persister cells in biofilm associated infections[A]//Advances in Experimental Medicine and Biology[M]. Cham:Springer International Publishing, 2014:1-9
    [54] Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria[J]. FEMS Microbiology Reviews, 2017, 41(3):276-301
    [55] Conlon BP. Staphylococcus aureus chronic and relapsing infections:evidence of a role for persister cells:an investigation of persister cells, their formation and their role in S. aureus disease[J]. BioEssays, 2014, 36(10):991-996
    [56] Gollan B, Grabe G, Michaux C, Helaine S. Bacterial persisters and infection:past, present, and progressing[J]. Annual Review of Microbiology, 2019, 73:359-385
    [57] Jorge P, Magalhães AP, Grainha T, Alves D, Sousa AM, Lopes SP, Pereira MO. Antimicrobial resistance three ways:healthcare crisis, major concepts and the relevance of biofilms[J]. FEMS Microbiology Ecology, 2019, 95(8):fiz115
    [58] Lopes SP, Jorge P, Sousa AM, Pereira MO. Discerning the role of polymicrobial biofilms in the ascent, prevalence, and extent of heteroresistance in clinical practice[J]. Critical Reviews in Microbiology, 2021, 47(2):162-191
    [59] El-Halfawy OM, Valvano MA. Non-genetic mechanisms communicating antibiotic resistance:rethinking strategies for antimicrobial drug design[J]. Expert Opinion on Drug Discovery, 2012, 7(10):923-933
    [60] Fusco DN, Alexander EL, Weisenberg SA, Mediavilla JR, Kreiswirth BN, Schuetz AN, Jenkins SG, Rhee KY. Clinical failure of vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant S. aureus[J]. Diagnostic Microbiology and Infectious Disease, 2009, 65(2):180-183
    [61] Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii[J]. Journal of Antimicrobial Chemotherapy, 2010, 65(2):233-238
    [62] Cheong JWS, Harris P, Oman K, Norton R. Challenges in the microbiological diagnosis and management of hVISA infections[J]. Pathology, 2011, 43(4):357-361
    [63] Sola C, Lamberghini RO, Ciarlantini M, Egea AL, Gonzalez P, Diaz EG, Huerta V, Gonzalez J, Corso A, Vilaro M, et al. Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of infective endocarditis in Argentina[J]. Annals of Clinical Microbiology and Antimicrobials, 2011, 10:15
    [64] Campanile F, Bongiorno D, Falcone M, Vailati F, Pasticci MB, Perez M, Raglio A, Rumpianesi F, Scuderi C, Suter F, et al. Changing Italian nosocomial-community trends and heteroresistance in Staphylococcus aureus from bacteremia and endocarditis[J]. European Journal of Clinical Microbiology& Infectious Diseases, 2012, 31(5):739-745
    [65] Silveira ACDO, Da Cunha GR, Caierão J, De Cordova CMM, D'Azevedo PA. Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil[J]. The Brazilian Journal of Infectious Diseases, 2015, 19(5):466-472
    [66] Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

张亚会,李文茹,谢小保. 铜绿假单胞菌异质性耐药的研究进展[J]. 微生物学通报, 2022, 49(3): 1167-1176

复制
相关视频

分享
文章指标
  • 点击次数:481
  • 下载次数: 1462
  • HTML阅读次数: 2732
  • 引用次数: 0
历史
  • 收稿日期:2021-08-23
  • 录用日期:2021-10-30
  • 在线发布日期: 2022-03-07
文章二维码
通信地址：北京市朝阳区北辰西路1号院3号中国科学院微生物研究所邮政编码：100101电话：010-64807511
网址：https://wswxtb.ijournals.cn/wswxtbcn/home E-mail：tongbao@im.ac.cn
微生物学通报 ® 2025 版权所有